959028-01-4

Basic information

• Product Name: 1H-Imidazole-4-carboxylic acid, 5-fluoro-, methyl ester
• Synonyms: 1H-Imidazole-4-carboxylic acid, 5-fluoro-, methyl ester
• CAS NO: 959028-01-4
• Molecular Formula: C5H5FN2O2
• Molecular Weight: 144.1
• Mol File: 959028-01-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Imidazole-4-carboxylic acid, 5-fluoro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-4-carboxylic acid, 5-fluoro-, methyl ester(959028-01-4)
• EPA Substance Registry System: 1H-Imidazole-4-carboxylic acid, 5-fluoro-, methyl ester(959028-01-4)

Safety Data

• Hazardous Substances Data: 959028-01-4(Hazardous Substances Data)

Usage

Chemical class

Imidazole group

Structure

Ester derivative of 5-fluoro-1H-imidazole-4-carboxylic acid with a methyl group replacing the hydrogen atom of the carboxylic acid group

Usage

Building block for the synthesis of various drugs and bioactive molecules in the pharmaceutical industry

Applications

Potential use in the treatment of various diseases and medical conditions due to its ability to modulate biological processes

Importance

Valuable tool in drug discovery and development due to its chemical structure and properties.

Relevant articles and documents

NOVEL INDAZOLE COMPOUND OR SALT THEREOF

An indazole compound represented by the following Formula (I) or a salt thereof: wherein X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this specification.

ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C

A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.

ETOMIDATE DERIVATIVE AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

The present invention discloses an etomidate derivative of Formula 1, or a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, a pharmaceutical composition and a kit comprising the same, as well as intermediates and methods for preparing the same, and use thereof. The etomidate derivative of the present invention not only has good anesthetic activity, rapid onset, and short duration of action, but also shows little inhibition to the secretion of corticosteroids in animals, and therefore has both favorable anesthetic effect and safety profiles.